Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies
- PMID: 20133382
- DOI: 10.1093/annonc/mdq009
Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies
Abstract
Background: Proteasome inhibition results in antitumor activity through various mechanisms, including disruption of cell cycle progression and control, induction of apoptosis, and inhibition of proliferation.
Design: This review assesses preclinical data on the ability of bortezomib, the first proteasome inhibitor approved for clinical use, to enhance antitumor activity of other agents and to overcome chemoresistance in hematologic malignancies and discusses mechanisms by which such activity arises.
Results: Bortezomib has been shown to affect multiple cellular pathways and levels of numerous intracellular proteins, including _targets of importance in hematologic malignancies. These mechanisms have shown additive or synergistic effects in vitro and in vivo with those of conventional therapeutic and novel _targeted agents. Additionally, _targets of proteasome inhibition are implicated in resistance or lack of sensitivity to different therapies. Bortezomib in combination with other agents has been shown to overcome resistance to those agents and to resensitize cells to agents to which they were previously unresponsive.
Conclusions: This review indicates the potential utility of proteasome inhibition for substantially enhancing activity of other therapeutic approaches. It explains the mechanisms responsible for the observed clinical activity of bortezomib-based regimens and elucidates novel therapeutic approaches through identification of combinations of agents with complimentary mechanisms of action.
Similar articles
-
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.Cancer. 2005 Nov 1;104(9):1794-807. doi: 10.1002/cncr.21414. Cancer. 2005. PMID: 16178003 Review.
-
Update on the proteasome inhibitor bortezomib in hematologic malignancies.Clin Lymphoma. 2004 Mar;4(4):230-7. doi: 10.3816/clm.2004.n.003. Clin Lymphoma. 2004. PMID: 15072615 Review.
-
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.Nat Clin Pract Oncol. 2006 Jul;3(7):374-87. doi: 10.1038/ncponc0555. Nat Clin Pract Oncol. 2006. PMID: 16826218 Review.
-
Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.Drugs Today (Barc). 2005 May;41(5):299-315. doi: 10.1358/dot.2005.41.5.893706. Drugs Today (Barc). 2005. PMID: 16082428 Review.
-
The potential of proteasome inhibitors in cancer therapy.Expert Opin Investig Drugs. 2008 Jun;17(6):879-95. doi: 10.1517/13543784.17.6.879. Expert Opin Investig Drugs. 2008. PMID: 18491989 Review.
Cited by
-
Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors.Cell Commun Signal. 2024 Feb 8;22(1):105. doi: 10.1186/s12964-023-01433-5. Cell Commun Signal. 2024. PMID: 38331801 Free PMC article. Review.
-
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.Blood. 2010 Dec 9;116(24):5285-8. doi: 10.1182/blood-2010-03-272393. Epub 2010 Sep 15. Blood. 2010. PMID: 20844234 Free PMC article.
-
Activation of ER Stress-Dependent miR-216b Has a Critical Role in Salviamiltiorrhiza Ethanol-Extract-Induced Apoptosis in U266 and U937 Cells.Int J Mol Sci. 2018 Apr 19;19(4):1240. doi: 10.3390/ijms19041240. Int J Mol Sci. 2018. PMID: 29671785 Free PMC article.
-
Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.Onco_target. 2014 Aug 30;5(16):7065-80. doi: 10.18632/onco_target.2295. Onco_target. 2014. PMID: 25216523 Free PMC article.
-
Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells.Onco_target. 2017 Feb 21;8(8):12741-12753. doi: 10.18632/onco_target.14405. Onco_target. 2017. PMID: 28055975 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
